

FluoGuide convenes an extraordinary general meeting

Copenhagen, Denmark, 7 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby invites shareholders to participate in an extraordinary general meeting to be held on 25 July 2023 at 11 AM CEST on Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.

To the shareholders of FluoGuide A/S

In continuance of the published press release regarding the Company's completion of a Directed Issue, the Company has to obtain an authorisation to issue warrants to the investors. The board of directors thus proposes that in addition to the subscription of shares, the investors participating in the Directed Share Issue, cf. press release regarding Directed Share Issue of 5 July 2023, should receive in aggregate 211,389 warrants, that each confer the right to subscribe nominal DKK 0.1 share.

The issuance of warrants is subject to the board of directors obtaining an authorization from the general meeting to issue the warrants and consequently the board of directors hereby convenes an extraordinary general meeting in FluoGuide in order to seek to obtain such authorisation. The extraordinary general meeting will be held on:

Tuesday 25 July 2023 at 11:00 (CEST)

at the Company's premises, Ole Maaløes Vej 3, room M0.10 - Neon, DK-2200 Copenhagen N, Denmark.

Please find the convening notice attached this press release. The convening notice can also be found on the Company's website: www.fluoguide.com/investor/general-meeting/

For further information, please contact:

Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com

Certified Adviser:

Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

About FluoGuide

FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. This improved precision enabled by FluoGuide's products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient's chance of achieving a complete cure and will lower system-wide healthcare costs. The Company has demonstrated efficacy of FG001 as well as it being well tolerated and safe in the completed proof-of-concept clinical study (phase I/IIa) in patients with aggressive brain cancer (high grade glioma) that undergo surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial. In addition, FluoGuide has explored FG001 in lung cancer, as well as in the ongoing phase IIa trial in head & neck cancer. Also a trial in meningioma and low grade glioma is commencing.

FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker "FLUO".

Read more about FluoGuides pipeline, technology and upcoming events on www.fluoguide.com

Attachments

[FluoGuide convenes an extraordinary general meeting](#)
[Invitation to extraordinary general meeting 2023](#)